DOI QR코드

DOI QR Code

Efficacy and safety of electrolytes-free polyethylene glycol (PEG) 4000 for disimpaction in children with chronic functional constipation

소아 만성 기능성변비 치료에서 전해질이 함유되지 않은 polyethylene glycol (PEG) 4000의 분변박힘 제거효과 및 안전성

  • Lee, Jeong Hee (Department of Pediatrics, School of Medicine, Konkuk University) ;
  • Lee, Ran (Department of Pediatrics, School of Medicine, Konkuk University) ;
  • Bae, Sun Hwan (Department of Pediatrics, School of Medicine, Konkuk University)
  • 이정희 (건국대학교 의학전문대학원 소아과학교실) ;
  • 이란 (건국대학교 의학전문대학원 소아과학교실) ;
  • 배선환 (건국대학교 의학전문대학원 소아과학교실)
  • Received : 2007.10.25
  • Accepted : 2007.11.29
  • Published : 2008.04.15

Abstract

Purpose : This study was performed evaluate optimal dose for disimpaction, efficacy and safety of PEG 4000 in children with chronic functional constipation. Methods : Eighty six children with chronic functional constipation were enrolled in this prospective study at Konkuk university hospital March, 2003 through August, 2006. Success in disimpaction with PEG 4000 was defined as meeting at least two out of three criteria; resolution of chief complaint, getting easiness of defecation with respect to frequency of bowel movement and hardness of stool based on defecation diary, and decrease in fecal impaction on simple abdominal X-ray test. Adverse effects of PEG 4000 were monitored clinically and biochemically. Results : Eighty three out of 86 children completed the study, and success rate of disimpaction was 99% (82/83). The mean dose of PEG 4000 for disimpaction was $0.93{\pm}0.28g/kg/day$ (0.4-2.0 g/kg/day, Max.: 30 g/day). Frequency of bowel movement increased ($5.02{\pm}2.71/wk$ vs. $11.25{\pm}5.43/wk$) in most children (79/83). Fecal impaction on simple abdominal X-ray test improved with statistical significance in 25 children (P=0.0007). Because of adverse effect of PEG 4000, 3 children did not complete the study; urticaria, severe diarrhea, diarrhea and abdominal pain. One 6-year-old girl who completed the study complained tingling sensation in the hand and foot without laboratory abnormality (4/86, 4.7%). Laboratory test revealed hyperosmolality without clinical symptom in 1 child, and eosinophilia in 6 children. Conclusion : The average safe and effective dose of PEG 4000 for disimpaction was $0.93{\pm}0.28g/kg/day$ (0.4-2.0 g/kg/day, Max : 30 g/day) in children with chronic functional constipation.

목 적 : 만성기능성 변비소아의 분변박힘제거 단계에서 전해질이 함유지 않은 PEG 4000의 적절한 용량, 효과 및 안전성에 대한 연구를 시행하였다. 방 법 : 2004년 3월부터 2006년 8월까지 건국대학교병원 소아과에서 만성기능성 변비로 진단된 환아 86명을 대상으로 전향적으로 시행하였으며, 주증상의 완화, 배변횟수와 배변 용이함의 향상, 복부 X선 검사 상 대변양의 감소 가운데 2가지를 충족하면 분변박힘제거가 성공적인 것으로 판단하였다. 치료효과를 판정하기위해 보호자나 환아가 기록한 변비 일지를 바탕으로 PEG 4000 복용전과 복용후의 주증상, 평균 배변횟수, 변의 굳기 및 단순 복부 X-선 사진을 비교하였으며, 임상적 증상 관찰과 함께 일반혈액검사와 전해질 검사, 칼슘, 마그네슘, 혈청삼투압검사를 시행하여 부작용을 확인하였다. 결 과 : 연구를 마친 83명 가운데 82명에서 분변박힘제거에 성공하였으며(99%), 분변박힘제거에 필요한 전해질이 함유되지 않은 PEG 4000의 평균용량은 $0.93{\pm}0.28g/kg/day$ (0.4-2.0 g/kg/day, 최대용량 30 g/day)이었다. 배변횟수는 83명 가운데 79명의 환아에서 치료 후에 배변횟수가 증가되었으며(평균 배변횟수 $5.02{\pm}2.71$회/1주 vs. $11.25{\pm}5.43$회/1주), 배변도 수월하고, 주증상도 거의 모든 환자에서 호전되었다. 치료 전후의 단순 복부 X-선 사진을 비교하였을 때, 통계학적으로 의미 있게 호전된 소견을 보였다(P=0.0007). 임상적으로 두드러기 1명, 심한 설사 1명과 설사와 복통 1명, 총 3명이 치료를 마치지 못하였으며, 대상 군에서는 손발 저림 증상이 1명에서 나타났으나, 약제 중단 후 아무런 처치 없이 호전되었다(4/86=4.7%). 검사소견상 1명에서 고삼투압혈증이 관찰되었으나, 임상적으로 증상이 관찰되지 않았으며, 6명에서 호산구 증가가 관찰되었다. 결 론 : 만성 기능성변비환아의 분변박힘제거에 안전하고 효과적인 PEG 4000 용량은 $0.93{\pm}0.28g/kg/day$ (최대용량 30 g/ day)로 생각된다.

Keywords

References

  1. Bae SH, So HS, Yoon HS, Hwang JS. Efficacy and safety of polyethylene glycol (PEG) with electrolytes for disimpaction in children with chronic functional constipation. J Korean Pediatr Soc 2003 Nov:46(11):1089-1094
  2. Youssef NN, Peters JM, Henderson W, Shultz-Peters S, Lockhart DK, Di Lorenzo C. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr 2002; 141:410-4 https://doi.org/10.1067/mpd.2002.126603
  3. Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. Aliment Pharmacol Ther 1993;7:523-9 https://doi.org/10.1111/j.1365-2036.1993.tb00128.x
  4. Loening-Baucke V, Krishna R, Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr 2004;39:536-9 https://doi.org/10.1097/00005176-200411000-00016
  5. Dupont C, Leluyer B, Amar F, Kalach N, Benhamou PH, Mouterde 0, et al. A dose determination study of polyethylene glycol 4000 in constipated children: Factors influencing the maintenance dose. J Pediatr Gastroenterol Nutr 2006:42:178-85 https://doi.org/10.1097/01.mpg.0000189349.17549.a9
  6. Benninga M, Candy DC, Catto-Smith AG, Clayden G, Loening-Baucke V, Di Lorenzo C, et al. The Paris consensus on childhood constipation terminology (PACCT) group. J Pediatr Gastroenterol Nutr 2005:40:273-5 https://doi.org/10.1097/01.MPG.0000158071.24327.88
  7. Cooks ley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24 Suppl 1:45-53 https://doi.org/10.1055/s-2004-828678
  8. Brady CE 3rd, DiPalma JA, Morawski SG, Santa Ana CA, Fordtran JS. Urinary excretion of polyethylene glycol 3350 and sulfate after gut lavage with a polyethylene glycol electrolyte lavage solution. Gastroenterology 1986;90:1914-8 https://doi.org/10.1016/0016-5085(86)90261-1
  9. Dipalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000;95:446-50 https://doi.org/10.1111/j.1572-0241.2000.01765.x
  10. Gremse DA, Hixon J, Crutchfield A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. Clin Pediatr (Phila) 2002:41:225-9 https://doi.org/10.1177/000992280204100405
  11. Rose M, Jacob LS. Seizure associated with use of visicol for colonoscopy N Engl J Med 2002;347:295-6
  12. Schroppel B, Segerer S, Keuneke C, Cohen C, Schlondorff D. Hyponatremic encephalopathy after preparation for colonoscopy. Gastrointest Endosc 2001;53:527-9 https://doi.org/10.1067/mge.2001.113274
  13. Ball SG, Baylis PH. Vasopressin, diabetes insipidus, and syndrome of inappropriate antidiuresis. In: DeGroot LJ, Jameson JL, de Kretser D, Grossman AB, Marshall JC, Melmed S, et aI., editors. Endocrinology 5th ed. Vol. 1. Philadelphia: WB Elsevier Co, 2006:537-52
  14. Michail S, Gendy E, Preud'Homme D, Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr 2004;39:197-9 https://doi.org/10.1097/00005176-200408000-00014

Cited by

  1. 소아 기능성 변비의 치료에 영향을 미치는 인자 vol.13, pp.1, 2008, https://doi.org/10.5223/kjpgn.2010.13.1.36
  2. Efficacy and Safety of Combined Oral and Enema Therapy Using Polyethylene Glycol 3350-Electrolyte for Disimpaction in Pediatric Constipation vol.20, pp.4, 2008, https://doi.org/10.5223/pghn.2017.20.4.244